Scopus Biopharma, Inc. (SCPS)
0.0004
0.00 (0.00%)
USD |
OTCM |
Oct 23, 16:00
Scopus Biopharma Max Drawdown (5Y) : 100.0% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 100.0% |
| August 31, 2026 | 100.0% |
| July 31, 2026 | 100.0% |
| June 30, 2026 | 100.0% |
| May 31, 2026 | 100.0% |
| April 30, 2026 | 100.0% |
| March 31, 2026 | 100.0% |
| February 28, 2026 | 100.0% |
| January 31, 2026 | 100.0% |
| December 31, 2025 | 100.0% |
| November 30, 2025 | 100.0% |
| October 31, 2025 | 100.0% |
| September 30, 2025 | 100.0% |
| August 31, 2025 | 100.0% |
| July 31, 2025 | 100.0% |
| June 30, 2025 | 100.0% |
| May 31, 2025 | 100.0% |
| April 30, 2025 | 100.0% |
| March 31, 2025 | 100.0% |
| February 28, 2025 | 100.0% |
| January 31, 2025 | 100.0% |
| December 31, 2024 | 100.0% |
| November 30, 2024 | 100.0% |
| October 31, 2024 | 100.0% |
| September 30, 2024 | 100.0% |
| Date | Value |
|---|---|
| August 31, 2024 | 100.0% |
| July 31, 2024 | 100.0% |
| June 30, 2024 | 100.00% |
| May 31, 2024 | 100.00% |
| April 30, 2024 | 100.00% |
| March 31, 2024 | 100.00% |
| February 29, 2024 | 100.00% |
| January 31, 2024 | 99.99% |
| December 31, 2023 | 99.91% |
| November 30, 2023 | 99.91% |
| October 31, 2023 | 99.91% |
| September 30, 2023 | 99.91% |
| August 31, 2023 | 99.91% |
| July 31, 2023 | 99.87% |
| June 30, 2023 | 99.86% |
| May 31, 2023 | 99.86% |
| April 30, 2023 | 99.86% |
| March 31, 2023 | 99.82% |
| February 28, 2023 | 99.82% |
| January 31, 2023 | 99.82% |
| December 31, 2022 | 99.82% |
| November 30, 2022 | 99.42% |
| October 31, 2022 | 99.33% |
| September 30, 2022 | 99.33% |
| August 31, 2022 | 98.98% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Windtree Therapeutics, Inc. | 100.0% |
| Navidea Biopharmaceuticals, Inc. | 100.0% |
| Biostax Corp. | 100.00% |
| Burzynski Research Institute, Inc. | 98.40% |
| GeneLink, Inc. | 99.99% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -393.44 |
| Beta (5Y) | 30.52 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 10.89K% |
| Historical Sharpe Ratio (5Y) | -0.0081 |
| Historical Sortino (5Y) | -0.9473 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 81.86% |